Home > Inhibitors & Agonists > Tyrosine Kinase > FLT3
Cat. No. Product name CAS No.
DC10922 AAE871

AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity..

289479-07-8
DC10921 ATH686 Featured

ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase.

853299-52-2
DC5159 CP-868596 (Crenolanib)

Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB

670220-88-9
DC8164 Gilteritinib(ASP2215) Featured

FLT3/AXL inhibitor

1254053-43-4
DC11780 FLT3-IN-5e

FLT3-IN-5e is a nove potent, selective FLT3 inhibitor with Kd of 3.6 nM, IC50 of <6 nM.

2093038-25-4
DC7792 G-749 Featured

G-749 is a novel selective inhibitor of FLT3 kinase as a therapeutics for AML with IC50 value of 0.4 nM for wild-type FLT31.

1457983-28-6
DC9286 K03861 Featured

K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.

853299-07-7
DC8522 KW-2449 Featured

KW 2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.

1000669-72-6
DC5197 Quizartinib (AC220) Featured

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 1/2.

950769-58-1
DC7894 Tandutinib(MLN518)

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2.

387867-13-2
DC28136 Tandutinib hydrochloride

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier.

DC28163 5'-Fluoroindirubinoxime Featured

5'-Fluoroindirubinoxime (5’-FIO, compound 13), an Indirubin derivative, is a potent FLT3 inhibitor, with an IC50 of 15 nM.

861214-33-7
Page 1 / Total 1 FirstPrevNextLastGoto